aap Implantate AGのEV / EBITDAはN/Aです。
EV / EBITDA は、企業価値をEBITDA（利息、税金、減価償却費および償却費を控除する前の利益）で割ったものですです。これは、株価がどれほど高価で、P / E比よりも頻繁に企業をお互いを比較するために使用されます。これは、投資家が会社のキャッシュフローの利益のために支払う価格を測定します。
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.